Purpose: The purpose of this study was to evaluate the incidence of thrombotic complications in patients with deep vein thrombosis (DVT) who were treated with percutaneous inferior vena caval interruption in place of anticoagulation.
underlying disease was pulmonary embolism in 15 (47%) and DVT in 17 (53%) patients. Of patients with pulmonary embolism, 11 had a documented DVT, and four were not evaluated for DVT. There were 14 men and 18 women, with a mean age of 63.5 years (range 24 to 93 years). Indications for vena caval interruption were recurrent pulmonary embolism with therapeutic anticoagulation (n = 2 [6%]), prophylactic insertion with documented pulmonary embolism and therapeutic anticoagulation (n = 8 [25%]), documented pulmonary embolism and absolute contraindication to anticoagulation (n = 5 [16%]), documented DVT and absolute contraindication to anticoagulation (n = 2 [6%]), prophylactic insertion with documented DVT and therapeutic anticoagulation (n ---5 [16%]), and documented DVT with relative contraindication to anticoagulation (n -10 [31%]). Of the 32 patients with inferior vena cava filters, 17 were not given anticoagulants (7 absolute contraindications, 10 relative contraindications), and 15 were given anticoagulants. Insertion of a percutaneous inferior vena cava filter in patients who were not given anticoagulants was followed by the development of phlegmasia cerulea dolens in four patients (24%), which was bilateral in two patients; one patient eventually died. No patients treated with inferior vena cava filter and anticoagulation had development of phlegmasia.
Conclusions:
Percutaneous inferior vena caval interruption effectively prevents pulmonary embolism in patients with DVT but does not impact the underlying thrombotic process and in fact may contribute to progressive thrombosis in patients who are not given anticoagulants. Anticoagulation with intravenous heparin is safe and effective therapy for DVT in most patients. We believe that percutaneous insertion ofvena cava filters should not replace anticoagulation in routine proximal DVT, and those patients who require an inferior vena cava filter for failure of anticoagulation should continue to receive heparin to treat the primary thrombotic process. We caution that relative contraindications to anticoagulation should be carefully scrutinized before recommending vena cava interruption as a primary therapy for DVT. ( Deep venous thrombosis (DVT) may be associated with two potentially serious acute complications: phlegmasia cerulea dolens and pulmonary embolism. Anticoagulation is the preferred treatment for DVT because it arrests the thrombotic process, allowing natural thrombolysis to occur, and is effective in preventing the development of phlegmasia cerulea dolens and pulmonary embolism. 14 Re-cent advances in percutaneous delivery systems have increased the use of vena caval interruption in thromboembolic disorders, s7 Placement ofvena cava filters in patients with documented pulmonary embolism or free-floating iliofemoral thrombus has been proven efficacious, but most of these patients continue to receive anticoagulants after inferior vena cava (1VC) filter placement. 8 Some advocate IVC filtration as the primary means of therapy in venous thromboembolic disease, without anticoagulation, but the effectiveness of this mode of therapy is unclear. 9 Others caution against the potential for overuse of the IVC filter.l° Controlled clinical trials to determine the role of IVC filters in DVT without pulmonary embolism or free-floating iliofemoral thrombus and without anticoagulation are lacking.
We have recently noted the development of phlegmasia cerulea dolens in patients with DVT who were treated with percutaneous vena caval interruption, without anticoagulation, as primary therapy for the DVT. To date only two isolated case reports address this potentially serious complication of vena caval interruption. We report the progression of four cases of DVT to phlegmasia after percutaneous interruption of the IVC in lieu of anticoagulation.
MATERIAL AND METHODS
The study population consisted of all patients discharged from Stanford University Medical Center during a 12-month period, from August 1, 1993 to July 31, 1994, with a diagnosis of acute DVT, pulmonary embolism, or both. A computerized registry of all hospital discharges was organized by International Classification of Diseases Ninth Revision and was searched for acute DVT and pulmonary embolism codes to generate a patient list of all patients with thromboembolic disease. This list was then searched for vena eaval interruption by catheter device or intravascular umbrella with use of Current Procedural Terminology coding of the procedures listed in the discharge summaries.
All patient records with catheter-directed vena caval interruption were then retrospectively reviewed to validate the procedure and the diagnosis of DVT or pulmonary embolism in patients included in the study. The diagnosis of DVT was made with use of color-flow duplex ultrasound examination of the lower extremities, ascending venography, or both examinations. The diagnosis of pulmonary embolism was made by use of high probability ventilationperfusion scanning or pulmonary angiography.
These records were then reviewed for demographic data including age, sex, indication for IVC filter, filter type, filter insertion site, concurrent medical conditions, risk factors for thromboembolism, and for use of anticoagulation. Patients were then categorized into two groups: group 1, IVC filter with anticoagulation, and group 2, IVC filter without anticoagulation.
The records were then reviewed for the presence of thrombotic complications developing after insertion of the vena cava filter. Phlegmasia cerulea dolens was defined as acute iliofemoral venous thrombosis associated with the sudden onset of severe leg pain, with swelling, edema, and cyanotic mottling. The presence of iliofemoral venous thrombosis was confirmed by duplex ultrasonography and venography. Therapy for the phlegmasia was recorded.
RESULTS
From August 1993 through July 1994, 306 cases of DVT and 135 cases of pulmonary embolism were diagnosed at Stanford University Hospital. Of these patients, 47 had both pulmonary embolism and DVT, so that the total number of patients with thromboembolic disease for this year was 394. From this group of patients with venous thromboembolic disease, 33 percutaneous IVC filters were placed in 32 patients for an incidence of vena caval filter insertion of 8%. The underlying disease in the patients receiving vena caval filters was pulmonary embolism in 15 (47%) and DVT in I7 (53%) patients. Diagnosis of pulmonary embolism was confirmed by pulmonary angiography in i3 patients (87%) and high probability ventilation-perfusion scanning in two patients (13%). Of patients with pulmonary embolism, l I patients had a coexistent DVT confirmed by duplex ultrasonography, and four patients were not evaluated for DVT. DVT was diagnosed by duplex ultrasonography in 17 patients without coexistent pulmonary embolism. In cases of DVT, the thrombus was limited to the popliteal or superficial femoral veins on initial evaluation in 94.2%.
Fourteen men and 18 women with a mean age of 63.5 years (range 24 to 93) comprised the study population. Risk factors for venous thromboembolism were neoplasm in i5 patients (47%), trauma in three patients (9%), postoperative state in five patients (16%), and chronic illness with bed rest in nine patients (28%).
Filter types included 30 titanium Greenfield filters (Medi-Tech, Inc., Watertown, Mass.), two Bird's Nest filters (Cook, Inc., Bloomington, Ind.), and one Venatech LGM filter (Vena-Tech, Evanston, Ill.) deployed in this series. The filter was deployed in the November 1995 internal jugular vein in 10 patients, in the common femoral vein in 22 patients, and via saphenous vein cutdown after operation in one patient. One patient had two Greenfield filters deployed sequentially through the same access site, the right common femoral vein, as a result of initial misplacement of the first filter. The initial filter deployed in this case was angulated and could not be adjusted, so the second filter was placed caudal to the first.
Grouped by indication for vena caval interruption, two patients (6%) had pulmonary embolism while receiving a full course of anticoagulant medication; eight patients (25%) were admitted with pulmonary embolism, were given anticoagulants, and underwent prophylactic insertion of an IVC filter; five patients (16%) were admitted with pulmonary embolism and absolute contraindication to anticoagulation; two patients (6%) were admitted with DVT and absolute contraindication to anticoagulation; five patients (16%) were admitted with DVT, were given anticoagulants, and underwent prophylactic insertion of an IVC filter; and 10 patients (31%) were admitted with DVT and a relative contraindication to anticoagulation. A more informative grouping is the presence or absence of anticoagulation with the vena cava filter. In patients with pulmonary embolism, 10 patients received heparin anticoagulation with the IVC filter, and five patients did not. In patients with DVT, five patients received heparin anticoagulation with the IVC filter, and 10 patients did not. Therefore 15 patients received heparin anticoagulation with the IVC filter, and 17 patients with IVC filter were not given anticoagulants.
• Phlegmasia cerulea dolens developed after placement of the vena caval filter in four of the 32 (12.5%) patients. No cases of phlegmasia cerulea dolens developed in the 15 patients with IVC filters receiving heparin anticoagulation. Therefore the incidence of phlegmasia developing in patients with IVC filters and no heparin anticoagulation was 23.5% (four of 17). In patients without documented pulmonary embolism or IVC filter and no heparin anticoagulation, the incidence of phlegmasia cerulea dolens was 33% (four of 12). One of these four patients had development of bilateral phlegmasia related to IVC thrombosis after filter placement.
The IVC filter was a titanium Greenfield type in all cases of phlegmasia cerulea dolens. The common femoral vein was the insertion sitc for the IVC filter in all cases of phlegmasia cerulea dolens. Phlegmasia cerulea dolens developed ipsilateral to the femoral vein insertion site in all cases. In two cases the insertion site was ipsilateral to the original DVT, and in two cases the insertion site was contralateral to the original DVT.
Phlegmasia cerulea dolens developed a mean of 4.5 days after insertion of the IVC filter (range 2 to 10 days). All cases of phlegmasia cerulea dolens had iliofemoral venous thrombosis confirmed by duplex scanning and ascending venography.
The stated reasons for not giving anticoagulants to the four patients with development of phlegmasia cerulea dolens were (1) development of DVT i4 days after craniotomy for ligation of an arteriovenous malformation in a 31-year-old man; (2) development of DVT in a 76-year-old man with prostatic cancer and remote history of lower gastrointestinal bleeding; (3) development of DVT 13 days after craniotomy and resection of a frontal meningioma in a 62-year-old woman; and (4) development of DVT 11 days after craniotomy and resection of a parietal meningioma in a 65-year-old woman who had development of left hemiparesis after the resection. Patient 4 had two filters placed as described above.
Patients 1 to 3 received heparin by continuous intravenous infusion, 100 units/kg load, and titration of an hourly infusion rate to maintain activated partial thromboplastin time (aPTT) between 1.5 and 2.5 times control after the diagnosis of phlegmasia was confirmed. The fourth patient was not given anticoagulant and had development of contralateral leg DVT and phlegmasia cerulea dolens within 48 hours. This patient had persistent pain and swelling, yet no gangrene, and was treated with leg elevation and, subsequently, sequential compression devices. The three patients receiving heparin had resolution of their pain and swelling, and medication was successfully changed to oral anticoagulants in two patients. Because of development of a heparin-associated antibody in the third patient, administration of heparin was discontinued, and oral anticoagulation with warfarin was begun. This 76-year-old man then had development of acute kidney failure, refused to undergo dialysis, and died 3 weeks after his admission to the hospital.
DISCUSSION
Venous thromboembolism represents a potentially fatal disease that, because of its often silent nature, its incidence, prevalence, and mortality rates are incompletely defined. The diagnosis of venous thromboembolism is largely limited to hospitalized patients, and most of our knowledge has been derived from this population. From a large community retrospective analysis, the average annual incidence of JOURNAL OF VASCULAR SURGERY Volume 22, Number 5 Harris et al. 609
DVT alone was 48 per 100,000, and the incidence of pulmonary embolism, with or without DVT was 23 per 100,000, and the incidence increased exponentially with increasing age. n It is estimated that pulmonary embolism is the primary cause of death in 100,000 patients annually and a contributing cause of death in another 100,000 patients annually in the United States. 12 Venous thromboembolic disease can be effectively managed by anticoagulation in most patients. 2,a When anticoagulation cannot be used, or when it fails, there is an indication for mechanical interruption of the vena cava to provide a barrier to thromboembolism. Indications for interruption of the IVC are (1) recurrent pulmonary embolism while adequate anticoagulants are administered; (2) pulmonary embolism or DVT with a contraindication to or complication from anticoagulation; (3) patients at high risk for pulmonary embolism despite adequate anticoagulation, such as a freefloating iliofemoral thrombus greater than 5 cm across; (4) in patients undergoing pulmonary embolectomy; (5) in patients undergoing elective operation with multiple risk factors for the development of thromboembolism or with prior history of venous thromboembolic disease, s Vena caval interruption has been predominantly managed by IVC filters since the initial introduction of these devices by their innovators 13Is and their clinical validation. 16-18 Subsequently, most of the published information on vena cava filters has been with the Greenfield filter, either stainless steel, or more recently titanium types. 19 Early experience with the Greenfield filter was notable for an IVC patency rate of 95%, with a recurrent pulmonary embolism rate of 5%. ~8 More recent experience with the titanium Greenfield filter showed no vena cava occlusions and prevention of recurrent pulmonary embolism in 97% of patients monitored over a more limited time span than the earlier study. 7 The mortality rate from filter complications alone has been low, 0.16% in 1632 patients in 16 series reporting experience with Greenfield vena caval filters, but filter complications have been common. 19,2°
Thrombotic complications of vena cava filters have been infrequently reported, yet significant variations in reporting standards complicate this issue. 19 Several reports have documented a 20% to 30% incidence of local femoral venous thrombosis at the insertion site of the vena cava filter. 21-23 Development ofphlegmasia cerulea dolens after placement of IVC filters has been less frequently reported in anecdotal case reports. 24,2s Worsening ofphlegmasia cerulea dolens after placement of an IVC filter has been more frequently observed. 26,27 Progression of DVT after placement of vena cava filters has been observed, often in patients who are believed to have a contraindication to anticoagulation yet ultimately require anticoagulation to control the thrombotic process. 27'2s Thus in most patients with DVT and indications for IVC filtration, concurrent anticoagulation is recommended, a position strongly advocated by Greenfield. z9 The definition of true contraindications for anticoagulation remains elusive. Clearly, patients with active ongoing hemorrhage and those with preexisting hemorrhagic disorders should not be given anticoagulants. Beyond these situations, no firm data exist contraindicating anticoagulation in other situations. Intuitively, recommendations against anticoagulation have been made in patients who have had "recent" surgery or trauma, yet the interval of time delimiting "recent" remains incompletely defined. Although the general risk of major bleeding from heparin anticoagulation approaches 5%, 30 there is no correlation between supratherapeutic aPTT levels while heparin therapy is used and bleeding. 31 In contrast there is evidence to support an increased incidence of recurrent venous thromboembolism with subtherapeutic aPTT levels while heparin therapy is used. 31 In a prospective study comparing intravenous heparin versus subcutaneous heparin therapies, there was a higher major hemorrhage rate in patients who had not had recent surgery than in those that had recent surgery. 32 It is from this study that the arbitrary 2-week postoperative time point arose, because the authors observed bleeding in patients less than 2 weeks after surgery, yet only two of 19 (10.5%) patients had major bleeding in this postoperative time period. The risk of major bleeding in the nonsurgical patients was 12.2% in the same study.
In most circumstances, heparin anticoagulation is effective in preventing pulmonary embolism in patients with venous thromboembolic disease. In patients with DVT, anticoagulation reduces the risk of fatal pulmonary embolism to a rate between 0.14% and 0.30%. 8,a3 In patients with a documented pulmonary embolism, heparin anticoagulation reduces the risk of recurrent fatal pulmonary embolism to a rate between 0.9% and 1.3%. 8,aa Furthermore, heparin anticoagulation retards the propagation of venous thrombosis in the calf and distal leg to the iliofemoral segments, diminishing the incidence of phlegmasia cerulea dolens.
In this series, the contraindications to anticoagu-lation were marginal, and in fact three of four patients who had development of phlegmasia while not receiving anticoagulants were subsequently given a full course of anticoagulant medication without bleeding complications. The one patient not given anticoagulants in this series most likely should have been. Furthermore, none of these four patients had their initial DVT extending into the iliofemoral venous segment. Perhaps in these patients with venous thromboembolic disease and a perceived risk for anticoagulation, one should return to operative venous thromboembolectomy before inserting a vena caval filter. Intraoperative pulmonary embolism is frequent during venous thrombectomies, yet fatal pulmonary embolism is rare. Long-term patency rates have been observed from 74% to 93%. 34 Arteriovenous fistula creation can obviate the need for anticoagulation after venous thromboembolectomy.
It is also interesting that all cases of phlegmasia cerulea dolens in this series developed ipsilateral to the common femoral venous insertion site. Others have reported an alarming incidence of local venous thrombosis at the insertion sites of vena cava filters, yet the incidence of concurrent anticoagulation in these series was not defined. [21] [22] [23] In a group of patients with documented venous thromboembolic disease who will not be given anticoagulants, the risk of extending the venous thrombotic process from an area of intimal injury must be magnified. Perhaps in this group of patients in need of vena caval interruption yet who are not candidates for anticoagulation, consideration of a jugular insertion site for vena cava filters should be given.
In all instances, the decision to place IVC filters in this series were made by the primary care team, without hematology or vascular surgery consultations. With the newer low-profile delivery systems, most IVC filters will most likely be placed in angiography suites, often at the directive of primary care physicians. Because vascular surgeons are consulted for the complications of acute and chronic DVT, we believe strongly that consultation from a vascular surgeon is also indicated during the analysis of treatment options for patients diagnosed with acute DVT.
Short-and long-term follow-up of these filters will be essential to help further define the role ofvena caval filtration in patients with venous thromboembolic disease. As Greenfield 29 cautions, "It is obvious that this new device has made filter insertion remarkably easy to accomplish. In the overall management of the patient with thrombotic disease, however, the filter has only a small role to play and it is incumbent on the physician who treats the patient to assume the responsibility for long term follow-up and care of the underlying disorder." From our experience, care of the underlying disorder should include anticoagulation if at all possible.
IVC interruption can be lifesaving in select situations. Percutaneous deployment of IVC filters prevents most pulmonary embolism in patients with DVT. Yet methods of IVC interruption do not impact on the underlying process of venous thrombosis and in fact may exacerbate the thrombotic process. Anticoagulation with intravenous heparin is safe and effective therapy for DVT in most patients, and true contraindications to anticoagulation remain incompletely defined. Anticoagulation should be maintained along with IVC filtration if at all possible. We believe percutaneous insertion ofvena cava filters should not replace anticoagulation in routine proximal DVT and caution that relative contraindications to anticoagulation should be carefully scrutinized before recommending vena caval interruption as a primary therapy for DVT. If a vena cava filter is required in a patient with DVT and who may not be given anticoagulant, consideration of a jugular vein insertion site is recommended.
